Darren Shepherd1, Yvonne Belessis2, Tamarah Katz2, John Morton2, Penny Field2, Adam Jaffe2. 1. Sydney Children's Hospital, High Street, Randwick, NSW 2031, Australia. Electronic address: Darren.Shepherd@sesiahs.health.nsw.gov.au. 2. Sydney Children's Hospital, High Street, Randwick, NSW 2031, Australia.
Abstract
OBJECTIVES: To determine the safety and efficacy of stoss therapy on vitamin D levels over a 12 month period in children with cystic fibrosis and vitamin D deficiency (<75 nmol/L). STUDY DESIGN: Retrospective chart review of 142 paediatric CF patients from 2007 till 2011. RESULTS: Thirty eight children received stoss therapy and 37 children with vitamin D deficiency were not treated and served as a control group. The stoss treated group had a significant and sustained increase in 25-hydroxyvitamin D levels measured at 1, 3, 6 and 12 months post treatment compared to controls (94.82 ± 41.0 nmol/L, p=0.001; 81.54 ± 24.6 nmol/L, p=0.001; 92.18 ± 36.5 nmol/L, p=0.008 and 64.6 ± 20.0 nmol/L, p=0.006 respectively). At 12 months post intervention, the mean difference in vitamin D levels from baseline between the stoss treated group and controls was significant at 15 nmol/L compared to 5 nmol/L (p=0.038). CONCLUSION: Stoss therapy effectively achieves and maintains levels of 25-hydroxyvitamin D greater than 75 nmol/L over 12 months.
OBJECTIVES: To determine the safety and efficacy of stoss therapy on vitamin D levels over a 12 month period in children with cystic fibrosis and vitamin D deficiency (<75 nmol/L). STUDY DESIGN: Retrospective chart review of 142 paediatric CFpatients from 2007 till 2011. RESULTS: Thirty eight children received stoss therapy and 37 children with vitamin D deficiency were not treated and served as a control group. The stoss treated group had a significant and sustained increase in 25-hydroxyvitamin D levels measured at 1, 3, 6 and 12 months post treatment compared to controls (94.82 ± 41.0 nmol/L, p=0.001; 81.54 ± 24.6 nmol/L, p=0.001; 92.18 ± 36.5 nmol/L, p=0.008 and 64.6 ± 20.0 nmol/L, p=0.006 respectively). At 12 months post intervention, the mean difference in vitamin D levels from baseline between the stoss treated group and controls was significant at 15 nmol/L compared to 5 nmol/L (p=0.038). CONCLUSION: Stoss therapy effectively achieves and maintains levels of 25-hydroxyvitamin D greater than 75 nmol/L over 12 months.
Authors: Chiara Bertolaso; Veronique Groleau; Joan I Schall; Asim Maqbool; Maria Mascarenhas; Norma E Latham; Kelly A Dougherty; Virginia A Stallings Journal: J Pediatr Gastroenterol Nutr Date: 2014-04 Impact factor: 2.839
Authors: Gregory Wallace; Sonata Jodele; Kasiani C Myers; Christopher E Dandoy; Javier El-Bietar; Adam Nelson; Cynthia B Taggart; Pauline Daniels; Adam Lane; Jonathan Howell; Ashley Teusink-Cross; Stella M Davies Journal: Biol Blood Marrow Transplant Date: 2016-04-01 Impact factor: 5.742
Authors: R Perchard; L Magee; A Whatmore; F Ivison; P Murray; A Stevens; M Z Mughal; S Ehtisham; J Campbell; S Ainsworth; M Marshall; M Bone; I Doughty; P E Clayton Journal: Endocr Connect Date: 2017-04-05 Impact factor: 3.335